Research & Treatment

Special Report: The Frontier of Bleeding Disorders Treatment

On February 23 and 24, an international group of researchers from universities, industry and government gathered in Washington, DC, for...

These grants are part of NHF’s increased commitment to funding critical bleeding disorders research.

Researcher Profiles, NBDF in Action

All of the funding for the JGP program comes from donations from NHF chapters and individuals.

We strive toward enrolling 2,000 confirmed hemophilia carriers in the MLOF Research Repository.

Like hepatitis C, hepatitis B is a viral infection in the liver. The infection can be acute or chronic, in...

For as long as he can remember, Jonathan Roberts, MD, knew he wanted to be a hematologist. Roberts was diagnosed...

The most common inherited bleeding disorder, von Willebrand disease (VWD) has also been one of the most difficult to diagnose...

Two subcutaneous therapies are currently being investigated.

MLOF is open to all people with hemophilia A and B.

More than 100 researchers met for NHF's 13th Workshop on Novel Technologies and Gene Transfer for Hemophilia.

The MLOF Research Repository will allow researchers to explore long-unanswered questions about hemophilia.

Epclusa® is the first all-oral drug to treat adults with chronic HCV infection from genotypes 1 to 6.